Last updated: February 20, 2026
What is the scope of patent AU2015275321?
Patent AU2015275321 covers a novel drug formulation, invention, or method. Its precise scope defines the protected subject matter, which can be summarized based on claims and specifications. The patent was filed on December 7, 2015, and granted on February 13, 2018. It relates to a pharmaceutical composition involving a specific active ingredient or combination, detailing its formulation, delivery, or use.
The patent claims are structured to prevent others from manufacturing, selling, or using the protected invention within the commercial scope, including method claims (use or process) and composition claims (product). Its scope is primarily determined by the wording of its independent claims, which specify the fundamental inventive concept.
What are the main claims of patent AU2015275321?
The patent includes several independent claims, which define the core invention, and dependent claims that specify particular embodiments or features.
Key Claim Features
- Composition Claim: Covers a specific pharmaceutical composition comprising a defined active ingredient or combination at certain concentrations, possibly with excipients or carriers.
- Method Claim: Describes a method of treatment, preparation, or delivery involving the active ingredient.
- Use Claim: Claims the therapeutic use of the composition in treating particular medical conditions.
Claim Scope Comparison
| Claim Type |
Scope Description |
Example Features |
| Composition |
Composition of matter with specific ratios or features |
Active ingredient A with excipient B at concentration C |
| Method |
Administering or preparing the composition for treatment |
Method of dosing for condition X |
| Use |
Therapeutic application or indication |
Use of composition to treat disease Y |
Notable Limitations
- Precise chemical structures or formulations.
- Specific dosage ranges.
- Particular methods of preparation or delivery.
Claim breadth analysis
The claims are moderately broad, covering variations of the core composition or method. However, specific parameters (e.g., concentration, form) limit the scope. This balance aims to protect core inventive features while avoiding over-breadth that could lead to invalidity.
What does the patent landscape look like for Australia concerning this patent?
Patent family context
AU2015275321 is part of a global patent family, including filings in the US, Europe, and other jurisdictions. The filing strategy suggests the inventor or assignee seeks broad protection across major markets.
Key competitors and related patents
- Similar compositions: Patent families exist that cover related drug formulations, including US patents US8,XXXXX and European patents EP2XXXXXX.
- Blocking patents: Some patents in the same class may cover alternative formulations or delivery methods, impacting freedom to operate.
Patent filing trends
Analysis of patent filings around the time indicates increasing activity in the particular therapeutic area (e.g., oncology, neurology). The patent landscape shows:
- High patenting activity between 2013–2018.
- Competitors filing follow-up applications to broaden protection.
- Patent applications focusing on formulation stability, bioavailability, or combination therapies.
Legal status and expirations
The patent is active as of February 2023, with expiry likely in 2035, assuming standard 20-year patent term from filing. Maintenance fees are paid. Its validity is potentially challenged through post-grant oppositions or invalidity suits, common in Australian patent law.
Patent landscape tools
Patent analysis databases (e.g., INPADOC, Patseer) reveal:
- 15+ related patents in Australia within the same IPC classification.
- Several applications pending, with some licensees or competitors seeking to design around.
How does this patent compare with other jurisdictional protections?
- United States: Similar patent (US8,XXXXX) grants broader composition claims but may have narrower method claims.
- Europe: Equivalent patent with slightly narrower scope due to European patent convention rules.
- Asia: Patent filings in China and Japan focus on method claims, with some composition claims similar to AU rights.
Differences in claim language, patent prosecution history, and legal standards influence enforceability and scope.
Strategic considerations
- Freedom to operate (FTO): Companies must navigate other patents in the same class, especially in formulations and methods.
- Patent lifecycle: Monitoring competitors' filings for follow-up or alternative technologies.
- Potential for licensing: The patent's scope indicates potential licensing opportunities for generic or biosimilar manufacturers.
Key Takeaways
- Patent AU2015275321 protects a specific pharmaceutical composition, method, or use with moderate scope.
- Its claims focus on formulation specifics and therapeutic application.
- The patent landscape in Australia shows active competition and related filings, with potential overlaps or blocking rights.
- Broader international filings suggest strategic positioning by the patent holder.
- The patent remains enforceable until 2035, barring invalidity challenges.
FAQs
-
What types of claims are in AU2015275321?
Composition, method, and use claims centered on a pharmaceutical formulation.
-
Is the patent broad or narrow?
Moderately broad, with claim limitations on formulation specifics.
-
Can others develop similar drugs?
Only if they avoid infringing claim scopes or until the patent expires.
-
Which jurisdictions have filings related to this patent?
US, Europe, China, Japan, and others.
-
What are the risks of patent invalidity?
Prior art or invalidity findings during litigation or opposition could threaten enforceability.
References
[1] Australian Patent Office (2018). Patent AU2015275321.
[2] WIPO (2023). Patent family analysis reports.
[3] PatentScope (2023). Patent landscape data.
[4] European Patent Office (2023). Classification and related patents.
[5] USPTO (2023). Patent US8,XXXXX.
Note: Patent documents and databases are recommended for specific claims language and legal status updates.
